A NINJA Initiative at Children's Mercy

Richard Ogden  
*Children's Mercy Kansas City*, rkogden@cmh.edu

Bradley A. Warady  
*Children's Mercy Hospital*, bwarady@cmh.edu

Vimal Chadha  
*Children's Mercy Hospital*, vchadha@cmh.edu

Wendy Hoebing  
*Children's Mercy Hospital*, whoebing@cmh.edu

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/posters

Part of the Medical Toxicology Commons, Nephrology Commons, Pediatrics Commons, Pharmaceutical Preparations Commons, and the Pharmacy and Pharmaceutical Sciences Commons

**Recommended Citation**

https://scholarlyexchange.childrensmercy.org/posters/37

This is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Posters by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Background

Nephrotoxic medication (NTMx) exposure is a common cause of acute kidney injury (AKI) in hospitalized children. A single center safety initiative was able to demonstrate a decrease in nephrotoxic-associated AKI by 62%. Subsequently, a multicenter pediatric institutional collaborative (NINJA: Nephrotoxic Injury Negated by Just in Time Action) was instituted at nine centers, including Children’s Mercy.

Methods

A key driver diagram was developed by the CMH NINJA team members. This was added to a “NINJA Roadshow” in which each participating medical division was informed about the metrics being measured (including % patients receiving 3 or more NTMx medications or an IV aminoglycoside for more than 3 days (“exposed”), and rate of exposed patients developing AKI on non-ICU patients). Six divisions were selected for the initial phase of implementation (Pulmonology, Cardiology, BMT, Hem/Onc, GI, Nephrology). Daily trigger reports were generated by the EMR and emailed to the clinical pharmacist on the respective medical services. The clinical pharmacist reviewed the list for NTMx exposure. If exposed, the pharmacist recommended a daily SCR and alternative, non-nephrotoxic medications, if available.

AIM STATEMENT

- Increase awareness of patients with nephrotoxic medication exposure and 61% decrease in the rate of AKI in all non-ICU patients.

- In 4 year time frame, we were able to demonstrate a 70% decrease in nephrotoxic medication exposure and 61% decrease in the rate of AKI in all non-ICU patients.

- Of the patients who were exposed, 12.4% developed AKI. The results at CMH were more favorable than the collaborative in overall exposure rate, AKI rate, and percent of patients who developed AKI following exposure.

Conclusions

By participation in a collaborative effort of NINJA leadership, medical divisions, and clinical pharmacists focused on limiting the use of nephrotoxic medications and reducing the risk of medication-related impairment of kidney function, we successfully decreased nephrotoxic medication exposure and the rate of AKI in non-ICU patients.